↓ Skip to main content

Dyskinesia

Overview of attention for book
Cover of 'Dyskinesia'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Brain Dopamine Receptors in Schizophrenia and Tardive Dyskinesia
  3. Altmetric Badge
    Chapter 2 Receptor-Binding Profiles of Neuroleptics
  4. Altmetric Badge
    Chapter 3 Functional Classification of Different Dopamine Receptors
  5. Altmetric Badge
    Chapter 4 Pharmacological Properties of Presynaptic Dopamine Receptor Agonists
  6. Altmetric Badge
    Chapter 5 Influence of GABA Mimetics and Lithium on Biochemical Manifestations of Striatal Dopamine Target Cell Hypersensitivity
  7. Altmetric Badge
    Chapter 6 New Aspects on the Role of Dopamine, Acetylcholine, and GABA in the Development of Tardive Dyskinesia
  8. Altmetric Badge
    Chapter 7 Differential Effects of Dopamine D-1 and D-2 Agonists and Antagonists in 6-Hydroxydopamine-Lesioned Rats
  9. Altmetric Badge
    Chapter 8 Is Tardive Dyskinesia a Unique Disorder?
  10. Altmetric Badge
    Chapter 9 Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors
  11. Altmetric Badge
    Chapter 10 Involuntary Disorders of Movement in Chronic Schizophrenia — The Role of the Illness and Its Treatment
  12. Altmetric Badge
    Chapter 11 Tardive dyskinesia: reversible and irreversible.
  13. Altmetric Badge
    Chapter 12 Pathophysiological Mechanisms Underlying Tardive Dyskinesia
  14. Altmetric Badge
    Chapter 13 Chemical and Structural Changes in the Brain in Patients with Movement Disorder
  15. Altmetric Badge
    Chapter 14 Medical treatment of dystonia.
  16. Altmetric Badge
    Chapter 15 The Effect of Dopamine Antagonists in Spontaneous and Tardive Dyskinesia
  17. Altmetric Badge
    Chapter 16 GABA Dysfunction in the Pathophysiology of Tardive Dyskinesia
  18. Altmetric Badge
    Chapter 17 Clinical Activity of GABA Agonists in Neuroleptic- and L -Dopa-Induced Dyskinesia
  19. Altmetric Badge
    Chapter 18 Tardive Dyskinesia: Nondopaminergic Treatment Approaches
  20. Altmetric Badge
    Chapter 19 Pathophysiology of L -Dopa-Induced Abnormal Involuntary Movements
  21. Altmetric Badge
    Chapter 20 Prevalence of Tardive Dyskinesia in a Clinic Population
  22. Altmetric Badge
    Chapter 21 Differential Alteration of Striatal D-1 and D-2 Receptors Induced by the Long-Term Administration of Haloperidol, Sulpiride or Clozapine to Rats
  23. Altmetric Badge
    Chapter 22 Pharmacological Differentiation of Dopamine D-1 and D-2 Antagonists After Single and Repeated Administration
  24. Altmetric Badge
    Chapter 23 Pathophysiology of Tardive Dyskinesia
  25. Altmetric Badge
    Chapter 24 Intermittent Treatment with Droperidol, a Short-Acting Neuroleptic, Increases Behavioral Dopamine Receptor Sensitivity
  26. Altmetric Badge
    Chapter 25 Induction and Reversal of Dopamine Dyskinesia in Rat, Cat, and Monkey
  27. Altmetric Badge
    Chapter 26 Behavioral Effects of Long-Term Neuroleptic Treatment in Cebus Monkeys
  28. Altmetric Badge
    Chapter 27 Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: a review.
Attention for Chapter 14: Medical treatment of dystonia.
Altmetric Badge

Mentioned by

wikipedia
2 Wikipedia pages

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Medical treatment of dystonia.
Chapter number 14
Book title
Dyskinesia
Published in
Psychopharmacology Supplementum, January 1985
DOI 10.1007/978-3-642-70140-5_14
Pubmed ID
Book ISBNs
978-3-64-270142-9, 978-3-64-270140-5
Authors

H Pakkenberg, B Pedersen, H. Pakkenberg, B. Pedersen, Pakkenberg, H., Pedersen, B.

Abstract

We review dystonia treatment results since 1981, including our own findings. Anticholinergics are still the most effective drugs, but less than 50% of patients continue with treatment. The authors recommend a combination of an anticholinergic, a benzodiazepine, and another drug (an antidopaminergic, carbamazepine, or fluperlapine) for the treatment of dystonia.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 2 67%
Professor 1 33%
Readers by discipline Count As %
Medicine and Dentistry 2 67%
Pharmacology, Toxicology and Pharmaceutical Science 1 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2015.
All research outputs
#7,454,951
of 22,790,780 outputs
Outputs from Psychopharmacology Supplementum
#2
of 4 outputs
Outputs of similar age
#7,301
of 38,835 outputs
Outputs of similar age from Psychopharmacology Supplementum
#2
of 2 outputs
Altmetric has tracked 22,790,780 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4 research outputs from this source. They receive a mean Attention Score of 3.5. This one scored the same or higher as 2 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 38,835 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.